Linked Data API

Show Search Form

Search Results

1137390
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16997 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16998 more like this
HL16999 more like this
star this property question first answered
less than 2019-07-15T10:23:54.303Zmore like thismore than 2019-07-15T10:23:54.303Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2168
unstar this property label Biography information for Baroness Morgan of Huyton more like this
1137391
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16998 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16997 more like this
HL16999 more like this
star this property question first answered
less than 2019-07-15T10:23:54.243Zmore like thismore than 2019-07-15T10:23:54.243Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2168
unstar this property label Biography information for Baroness Morgan of Huyton more like this
1137392
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16999 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16997 more like this
HL16998 more like this
star this property question first answered
less than 2019-07-15T10:23:54.35Zmore like thismore than 2019-07-15T10:23:54.35Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2168
unstar this property label Biography information for Baroness Morgan of Huyton more like this
1132403
star this property registered interest false more like this
star this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi. more like this
star this property tabling member constituency Birmingham, Selly Oak more like this
star this property tabling member printed
Steve McCabe more like this
star this property uin 265417 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> more like this
unstar this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 265418 more like this
star this property question first answered
less than 2019-06-20T09:33:36.433Zmore like thismore than 2019-06-20T09:33:36.433Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
298
unstar this property label Biography information for Steve McCabe more like this
1122669
star this property registered interest false more like this
star this property date less than 2019-04-24more like thismore than 2019-04-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the value of packs of Orkambi that have been disposed of while negotiations between NHS England and Vertex Pharmaceuticals are ongoing. more like this
star this property tabling member constituency North East Hampshire more like this
star this property tabling member printed
Mr Ranil Jayawardena more like this
star this property uin 247136 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-05-03more like thismore than 2019-05-03
star this property answer text <p>The Department has made no such estimate.</p> more like this
unstar this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-03T13:18:10.21Zmore like thismore than 2019-05-03T13:18:10.21Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
4498
unstar this property label Biography information for Mr Ranil Jayawardena more like this
1104818
star this property registered interest false more like this
star this property date less than 2019-03-25more like thismore than 2019-03-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to secure a deal with Vertex on access for patients to the drug Orkambi on the NHS. more like this
star this property tabling member constituency Leeds North West more like this
star this property tabling member printed
Alex Sobel more like this
star this property uin 236525 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-04-01more like thismore than 2019-04-01
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals on access to their portfolio of cystic fibrosis medicines, including Orkambi.</p><p> </p><p>The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the NHS.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care held a meeting on 11 March with all the parties to discuss how best to reach a deal so that people with cystic fibrosis and their families can benefit as soon as possible. Vertex, NICE and NHS England subsequently met on Thursday 21 March and have agreed to continue discussions.</p> more like this
unstar this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-04-01T11:40:40.363Zmore like thismore than 2019-04-01T11:40:40.363Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
unstar this property tabling member
4658
unstar this property label Biography information for Alex Sobel more like this
1088522
star this property registered interest false more like this
star this property date less than 2019-03-13more like thismore than 2019-03-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 January 2018 to Question 122336 on Orkambi, whether he has made an estimate of the potential savings accruing to the public purse from reduced hospital admissions in the event that Orkambi is made available on the NHS. more like this
star this property tabling member constituency Glasgow East more like this
star this property tabling member printed
David Linden more like this
star this property uin 232091 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-03-21more like thismore than 2019-03-21
star this property answer text <p>As stated in my answer on 19 January 2018, the Department has made no estimate.</p> more like this
unstar this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-03-21T16:17:12.057Zmore like thismore than 2019-03-21T16:17:12.057Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
unstar this property tabling member
4640
unstar this property label Biography information for David Linden more like this
1088523
star this property registered interest false more like this
star this property date less than 2019-03-13more like thismore than 2019-03-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 January 2018 to Question 122358 on Orkambi: Republic of Ireland, whether he has had further discussions with his Irish counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis. more like this
star this property tabling member constituency Glasgow East more like this
star this property tabling member printed
David Linden more like this
star this property uin 232092 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-03-21more like thismore than 2019-03-21
star this property answer text <p>The Department has had no further discussions with the Republic of Ireland in relation to Orkambi.</p> more like this
unstar this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-03-21T16:18:55.757Zmore like thismore than 2019-03-21T16:18:55.757Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
unstar this property tabling member
4640
unstar this property label Biography information for David Linden more like this
1059846
star this property registered interest false more like this
star this property date less than 2019-02-12more like thismore than 2019-02-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will place in the Library a copy of his response to the technical submission, contained in the letter to him dated 31 January 2019 from patients and campaigners on issuing a Crown Use License to make Orkambi available to all eligible patients in England; and if he will make a statement. more like this
star this property tabling member constituency Brighton, Pavilion more like this
star this property tabling member printed
Caroline Lucas more like this
star this property uin 220176 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-20more like thismore than 2019-02-20
star this property answer text <p>We have received the letter dated 31 January and we will respond in due course.</p> more like this
unstar this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-02-20T17:42:05.587Zmore like thismore than 2019-02-20T17:42:05.587Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
unstar this property tabling member
3930
unstar this property label Biography information for Caroline Lucas more like this
1060036
star this property registered interest false more like this
star this property date less than 2019-02-12more like thismore than 2019-02-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of using a Crown licence obtain the drug Orkambi at an affordable price. more like this
star this property tabling member constituency East Antrim more like this
star this property tabling member printed
Sammy Wilson more like this
star this property uin 220162 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-20more like thismore than 2019-02-20
star this property answer text <p>It is right that patients should have access to cost-effective, innovative medicines at a price that is affordable to the National Health Service. As explained in the adjournment debate on 4 February, the Government is clear Crown Use is not a quick or easy solution but it is important we consider all options.</p><p> </p><p>The manufacturer, Vertex, needs to agree the very generous offer that has been made so that patients who need Orkambi are able to access it on the NHS. This is in the best interests of patients.</p> more like this
unstar this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-02-20T17:27:59.407Zmore like thismore than 2019-02-20T17:27:59.407Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
unstar this property tabling member
1593
unstar this property label Biography information for Sammy Wilson more like this